Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Beckman Coulter, Wyatt Technology Partner

Published: Tuesday, March 04, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
The companies will develop and market products designed for nanoparticle characterization.

Beckman Coulter Life Sciences announced an agreement with Wyatt Technology Corporation enabling collaboration on products, applications and technical development.  The partnership brings together Wyatt’s expertise in protein characterization, light scattering and biophysics with Beckman Coulter’s expertise in particle counting, particle characterization and cell viability measurement.

“We are excited to be working with Wyatt Technology, as they have strong brand recognition in sectors such as biopharmaceuticals. Their products are already known by our Vi-Cell and analytical ultracentrifuge customers,” said Matt Rhyner, PhD, senior marketing manager, Beckman Coulter Life Sciences.  “Partnering with Wyatt Technology, a storied company renowned for their technology and products, will help us expand our portfolio and presence in the particle market.”

The accord specifies that the companies will develop products for nanoparticle characterization to be marketed under the Beckman Coulter Life Sciences brand, and opens the door for future collaborations on product development and the sharing of business practices.

“Collaboration with Beckman Coulter has been of interest since getting to know Wallace Coulter in the late 1970s,” explained Dr. Philip Wyatt, chief executive officer, Wyatt Technology. “Entering into this agreement with a company that has the history and strong product portfolio of Beckman Coulter, we see a great opportunity to expand market access while retaining the strength and character upon which our customers rely.”

Taken together with the recent addition of the MET ONE and HIAC brands, the accord with Wyatt enables Beckman Coulter to provide a greater range of particle characterization solutions and to further enhance their world-class customer support and service.

Currently being introduced at Pittcon 2014 Booth 1964, the Multisizer 4e COULTER COUNTER is the latest Beckman Coulter innovation in particle counting and characterization, measuring particles as small as 0.2 microns.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
Sanofi Working on Zika Vaccine with U.S. Army
Sanofi is working in conjunction with the U.S. Army to develop possible Zika vaccine at faster rate following research agreement.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!